# Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

> **NCT00036400** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 60 (actual)

## Conditions studied

- Stomach Neoplasms
- Rectal Neoplasms

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00036400
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** —
- **Final completion:** 2003-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2011-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036400, "Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00036400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*